Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nixed Remicade Patent Clears Way For Pfizer/Celltrion Biosimilar Launch

Executive Summary

A Massachusetts court's ruling invalidating a patent on Johnson & Johnson's Remicade (infliximab) appears to clear the way for Pfizer Inc. and Celltrion Inc. to finally launch their FDA-licensed biosimilar Inflectra (infliximab-dyyb). J&J, however, said it plans to appeal and any biosimilar launch would be considered "at risk."

You may also be interested in...



Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales

Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.

Novartis/Sandoz Biosimilar Erelzi OK'd; Covets Enbrel's US Sales

Novartis AG unit Sandoz Inc. won US approval of its biosimilar Erelzi, which is referenced on Amgen's tumor necrosis factor blocker Enbrel (etanercept). The product, however, currently is caught in a patent dispute, although a recent stipulation has provided some hope for a smoother path through the legal jungle than other biosimilars may face.

Pfizer/Celltrion Prep For October Inflectra Launch

With Celltrion shipping the first batch of its biosimilar Inflectra (infliximab-dyyb) and a stipulation agreement with Johnson & Johnson, Pfizer is set to launch the product on Oct. 3 – six months after it was approved in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel